BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 17325587)

  • 1. Stimulation test in the follow-up of thyroid cancer: plasma rhTSH levels are dependent on body weight, not endogenously stimulated TSH values.
    Zanotti-Fregonara P; Duron F; Keller I; Khoury A; Devaux JY; Hindié E
    Nucl Med Commun; 2007 Apr; 28(4):257-9. PubMed ID: 17325587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.
    Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Biondi B; Iorio S; Giustina A; Amato G; Carella C
    J Bone Miner Res; 2005 Mar; 20(3):480-6. PubMed ID: 15746993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer.
    Montesano T; Durante C; Attard M; Crocetti U; Meringolo D; Bruno R; Tumino S; Rubello D; Al-Nahhas A; Colandrea M; Maranghi M; Travascio L; Ronga G; Torlontano M
    Biomed Pharmacother; 2007 Sep; 61(8):468-71. PubMed ID: 17553654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
    Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
    Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of (131)I.
    Menzel C; Kranert WT; Döbert N; Diehl M; Fietz T; Hamscho N; Berner U; Grünwald F
    J Nucl Med; 2003 Jul; 44(7):1065-8. PubMed ID: 12843221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum thyrotropin (TSH) levels after recombinant human TSH injections in children and teenagers with papillary thyroid cancer.
    Iorcansky S; Herzovich V; Qualey RR; Tuttle RM
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6553-5. PubMed ID: 16174712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human thyroid-stimulating hormone (rhTSH): clinical development.
    Incerti C
    J Endocrinol Invest; 1999; 22(11 Suppl):8-16. PubMed ID: 10727000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.
    Tuttle RM; Brokhin M; Omry G; Martorella AJ; Larson SM; Grewal RK; Fleisher M; Robbins RJ
    J Nucl Med; 2008 May; 49(5):764-70. PubMed ID: 18413378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of recombinant thyroid-stimulating hormone (rhTSH) in the detection and management of well-differentiated thyroid carcinoma: a roundtable discussion.
    Schlumberger MJ; Incerti C; Pacini F; Reiners C
    J Endocrinol Invest; 1999; 22(11 Suppl):35-41. PubMed ID: 10727004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uses for recombinant human TSH in patients with thyroid cancer and nodular goiter.
    Woodmansee WW; Haugen BR
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):163-73. PubMed ID: 15272910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
    Vrachimis A; Schober O; Riemann B
    Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human thyroid-stimulating hormone (Thyrogen) in thyroid cancer follow up: experience at a single institution.
    Wong R; Topliss DJ; Bach LA; Hamblin PS; Kalff V; Long F; Stockigt JR
    Intern Med J; 2009 Mar; 39(3):156-63. PubMed ID: 19383064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of recombinant human TSH aided radioiodine doses administered in patients with differentiated thyroid carcinoma.
    Pitoia F; Tamer EE; Schere DB; Passerieu M; Bruno OD; Niepomniszcze H
    Medicina (B Aires); 2006; 66(2):125-30. PubMed ID: 16715760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Response of thyroglobulin, anti-thyroglobulin antibodies, TSH, FT4 and total T3 after rhTSH stimulation in differentiated thyroid carcinoma].
    Moreno Ortega E; Vallejo Casas JA; Mena Bares LM; del Real Núñez R; Maza Muret FR; Hidalgo Ramos FJ; Latre Romero JM
    Rev Esp Med Nucl; 2008; 27(4):253-8. PubMed ID: 18682151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients.
    Pötzi C; Moameni A; Karanikas G; Preitfellner J; Becherer A; Pirich C; Dudczak R
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):519-23. PubMed ID: 16984246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.
    Taïeb D; Sebag F; Cherenko M; Baumstarck-Barrau K; Fortanier C; Farman-Ara B; De Micco C; Vaillant J; Thomas S; Conte-Devolx B; Loundou A; Auquier P; Henry JF; Mundler O
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):115-23. PubMed ID: 18803678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
    Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
    J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer.
    Pacini F; Castagna MG
    Best Pract Res Clin Endocrinol Metab; 2008 Dec; 22(6):1009-21. PubMed ID: 19041828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of administering 0.2 mg of recombinant human TSH for two consecutive days as an adjuvant to therapy with low radioiodine doses in elderly out-patients with large nontoxic multinodular goiter.
    Giusti M; Cappi C; Santaniello B; Ceresola E; Augeri C; Lagasio C; Minuto F
    Minerva Endocrinol; 2006 Sep; 31(3):191-209. PubMed ID: 17213787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): whole-body scanning with iodine-131.
    Reiners C; Luster M; Lassmann M
    J Endocrinol Invest; 1999; 22(11 Suppl):17-24. PubMed ID: 10727001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.